Pancreatic Cancer Research

ResearcherJohannes Gutenberg University MainzActive in the last 2 years

Oliver Holger Krämer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3973-045X; OpenAlex author ID A5049942833, A5081384737. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 4 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 15

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair. Co-author DOI 10.1136/gutjnl-2025-336227↗
  3. The protein phosphatase-2A subunit PR130 is involved in the formation of cytotoxic protein aggregates in pancreatic ductal adenocarcinoma cells. Last author DOI 10.1186/s12964-024-01597-8↗
  4. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Co-author DOI 10.1002/cac2.12280↗
  5. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  6. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Co-author DOI 10.1073/pnas.2105691119↗
  7. HDAC2 Facilitates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-3209↗
  8. Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Murine Pancreatic Cancer Cells upon dNTP Depletion. Last author DOI 10.3390/cells10102520↗
  9. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Co-author DOI 10.1002/1878-0261.12835↗
  10. MTOR inhibitor-based combination therapies for pancreatic cancer. Co-author DOI 10.1038/bjc.2017.421↗
  11. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Co-author DOI 10.1038/onc.2016.344↗
  12. Concepts to Target MYC in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-16-0050↗
  13. Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death. Co-author DOI 10.1002/ijc.27916↗
  14. A ZEB1-HDAC pathway enters the epithelial to mesenchymal transition world in pancreatic cancer. First author DOI 10.1136/gutjnl-2011-301576↗
  15. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s12029-011-9257-1↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Günter Schneider · 14 shared papers, 2011–2026 · strength 1.46
  2. Matthias Wirth · 10 shared papers, 2013–2026 · strength 1.01
  3. Maximilian Reichert · 9 shared papers, 2013–2026 · strength 0.93
  4. Dieter Saur · 10 shared papers, 2011–2026 · strength 0.90
  5. Roland Rad · 7 shared papers, 2017–2026 · strength 0.77
  6. Christian Schneeweis · 5 shared papers, 2018–2026 · strength 0.60
  7. Janine Murr · 3 shared papers, 2021–2026 · strength 0.59
  8. Alexandra Nguyen · 3 shared papers, 2021–2026 · strength 0.59
  9. Zonera Hassan · 6 shared papers, 2017–2022 · strength 0.59
  10. Lukas Krauß · 4 shared papers, 2022–2026 · strength 0.56
  11. Carolin Schneider · 4 shared papers, 2022–2026 · strength 0.56
  12. Elisabeth Heßmann · 3 shared papers, 2022–2026 · strength 0.51
  13. Roland Michael Schmid · 6 shared papers, 2011–2026 · strength 0.50
  14. Felix Orben · 3 shared papers, 2022–2026 · strength 0.44
  15. Ulrich Bernd Keller · 3 shared papers, 2020–2026 · strength 0.41
  16. Volker Ellenrieder · 2 shared papers, 2026 · strength 0.39
  17. Marian Grade · 2 shared papers, 2022–2026 · strength 0.31
  18. Hazal Köse · 2 shared papers, 2022–2026 · strength 0.31
  19. Alexander Arlt · 3 shared papers, 2017–2022 · strength 0.24
  20. Josefina Doffo · 2 shared papers, 2020–2022 · strength 0.22
  21. Katharina Lankes · 2 shared papers, 2020–2022 · strength 0.21
  22. Shiv K. Singh · 1 shared paper, 2026 · strength 0.20
  23. Muhammad Umair Latif · 1 shared paper, 2026 · strength 0.20
  24. Ulrich Sax · 1 shared paper, 2026 · strength 0.20
  25. Lena‐Christin Conradi · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.